Skip to main content
. 2016 Jul 18;95(28):e4144. doi: 10.1097/MD.0000000000004144

Figure 2.

Figure 2

CSF and plasma biomarkers of immune activation and neurodegeneration in patients receiving either atazanavir/ritonavir monotherapy or atazanavir/ritonavir containing triple therapy. Full dots represent the patient with CSF escape. P values were calculated by Wilcoxon rank-sum test. ATV/r = atazanavir/ritonavir, CSF = cerebrospinal fluid, NRTIs = nucleoside reverse transcriptase inhibitors.